Skip to main content
Erschienen in: Journal of Radiation Oncology 3/2017

11.03.2017 | Original Research

Radiation therapy for localized malignant pleural mesothelioma: a propensity score-matched analysis of the National Cancer Data Base

verfasst von: Nisha Ohri, Emanuela Taioli, Bian Liu, Andrea Wolf, Jorge Gomez, Raja Flores, Kenneth E. Rosenzweig

Erschienen in: Journal of Radiation Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

The objectives of this study were to analyze rates of radiation therapy (RT) utilization for malignant pleural mesothelioma (MPM) and evaluate the association between RT and overall survival (OS).

Methods

The National Cancer Data Base (NCDB) was queried to identify patients with non-metastatic MPM diagnosed between 2004 and 2013. RT was defined as receipt of 40-65Gy of external beam radiation therapy to the chest wall, lungs, or pleura. Multivariable logistic regression was performed to identify predictors of RT receipt. OS was estimated using the Kaplan-Meier method. Propensity score matching was performed to verify the effect of RT on OS.

Results

Among 14,090 MPM patients, 3.6% received RT. Younger age, lower co-morbidity score, private insurance, surgical resection, and receipt of chemotherapy were associated with increased RT utilization. Patients who received RT had higher crude 2 and 5-year OS rates (33.9 and 12.6%, respectively) compared to patients who did not (19.5 and 5.3%, respectively; p < 0.001). In multivariable analysis and propensity matched analysis, definitive RT was significantly associated with improved survival (adjusted hazard ratio [adj HR] 0.78, 95% CI 0.70–0.87) and (adj HR 0.77, 95% CI 0.67–0.89), respectively. Compared to no therapy, surgery and RT (adj HR 0.41, 95% CI 0.31–0.54) and trimodality therapy (adj HR 0.47, 95% CI 0.40–0.55) were associated with the best survival.

Conclusions

The rate of RT utilization for non-metastatic MPM has remained low over the past decade. Patients who received RT had improved OS. Combined modality therapy was associated with a greater improvement in survival than single modality treatment.
Literatur
1.
Zurück zum Zitat Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644CrossRefPubMed Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644CrossRefPubMed
2.
Zurück zum Zitat Zalcman G, Mazieres J, Margery J, et al: Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet, 2015 Zalcman G, Mazieres J, Margery J, et al: Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet, 2015
3.
Zurück zum Zitat Taioli E, Wolf AS, Flores RM (2015a) Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg 99:472–480CrossRefPubMed Taioli E, Wolf AS, Flores RM (2015a) Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg 99:472–480CrossRefPubMed
4.
Zurück zum Zitat Rusch VW, Rosenzweig K, Venkatraman E et al (2001) A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122:788–795CrossRefPubMed Rusch VW, Rosenzweig K, Venkatraman E et al (2001) A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122:788–795CrossRefPubMed
5.
Zurück zum Zitat Krug LM, Pass HI, Rusch VW et al (2009) Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27:3007–3013CrossRefPubMedPubMedCentral Krug LM, Pass HI, Rusch VW et al (2009) Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27:3007–3013CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Stahel RA, Riesterer O, Xyrafas A et al (2015) Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 16:1651–1658CrossRefPubMed Stahel RA, Riesterer O, Xyrafas A et al (2015) Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 16:1651–1658CrossRefPubMed
7.
Zurück zum Zitat Rimner A, Zauderer MG, Gomez DR, et al (2016a) Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol Rimner A, Zauderer MG, Gomez DR, et al (2016a) Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol
8.
Zurück zum Zitat Rimner A, Simone CB 2nd, Zauderer MG et al (2016b) Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power? Lancet Oncol 17:e43–e44CrossRefPubMed Rimner A, Simone CB 2nd, Zauderer MG et al (2016b) Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power? Lancet Oncol 17:e43–e44CrossRefPubMed
9.
Zurück zum Zitat Steele GD Jr, Winchester DP, Menck HR (1994) The National Cancer Data Base. A mechanism for assessment of patient care Cancer 73:499–504PubMed Steele GD Jr, Winchester DP, Menck HR (1994) The National Cancer Data Base. A mechanism for assessment of patient care Cancer 73:499–504PubMed
10.
Zurück zum Zitat Taioli E, Wolf AS, Camacho-Rivera M et al (2015b) Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients. PLoS One 10:e0145039CrossRefPubMedPubMedCentral Taioli E, Wolf AS, Camacho-Rivera M et al (2015b) Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients. PLoS One 10:e0145039CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Batirel HF, Metintas M, Caglar HB et al (2008) Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol 3:499–504CrossRefPubMed Batirel HF, Metintas M, Caglar HB et al (2008) Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol 3:499–504CrossRefPubMed
12.
Zurück zum Zitat Flores RM, Krug LM, Rosenzweig KE et al (2006) Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 1:289–295CrossRefPubMed Flores RM, Krug LM, Rosenzweig KE et al (2006) Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 1:289–295CrossRefPubMed
13.
Zurück zum Zitat Yajnik S, Rosenzweig KE, Mychalczak B et al (2003) Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 56:1319–1326CrossRefPubMed Yajnik S, Rosenzweig KE, Mychalczak B et al (2003) Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 56:1319–1326CrossRefPubMed
14.
Zurück zum Zitat Gupta V, Mychalczak B, Krug L et al (2005) Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 63:1045–1052CrossRefPubMed Gupta V, Mychalczak B, Krug L et al (2005) Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 63:1045–1052CrossRefPubMed
15.
Zurück zum Zitat Miles EF, Larrier NA, Kelsey CR et al (2008) Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys 71:1143–1150CrossRefPubMed Miles EF, Larrier NA, Kelsey CR et al (2008) Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys 71:1143–1150CrossRefPubMed
16.
Zurück zum Zitat Rice DC, Smythe WR, Liao Z et al (2007) Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 69:350–357CrossRefPubMed Rice DC, Smythe WR, Liao Z et al (2007) Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 69:350–357CrossRefPubMed
17.
Zurück zum Zitat Allen AM, Czerminska M, Janne PA et al (2006) Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65:640–645CrossRefPubMed Allen AM, Czerminska M, Janne PA et al (2006) Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65:640–645CrossRefPubMed
18.
Zurück zum Zitat Patel PR, Yoo S, Broadwater G et al (2012) Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 83:362–368CrossRefPubMed Patel PR, Yoo S, Broadwater G et al (2012) Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 83:362–368CrossRefPubMed
Metadaten
Titel
Radiation therapy for localized malignant pleural mesothelioma: a propensity score-matched analysis of the National Cancer Data Base
verfasst von
Nisha Ohri
Emanuela Taioli
Bian Liu
Andrea Wolf
Jorge Gomez
Raja Flores
Kenneth E. Rosenzweig
Publikationsdatum
11.03.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Radiation Oncology / Ausgabe 3/2017
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-017-0299-2

Weitere Artikel der Ausgabe 3/2017

Journal of Radiation Oncology 3/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.